ACOR(Delisted)
Acorda Therapeutics·NASDAQ
--
--(--)
ACOR fundamentals
Acorda Therapeutics (ACOR) released its earnings on Oct 31, 2017: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Oct 31, 2017
EPS
Revenue
Revenue & Expenses
ACOR has released its 2023 Q4 earnings report, with revenue of 37.98M, reflecting a YoY change of 20.70%, and net profit of -217.76M, showing a YoY change of -1237.61%. The Sankey diagram below clearly presents ACOR's revenue sources and cost distribution.
Key Indicators
Acorda Therapeutics (ACOR) key financial stats and ratios, covering profitability, financial health, and leverage.
Acorda Therapeutics (ACOR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Acorda Therapeutics (ACOR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Acorda Therapeutics (ACOR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Acorda Therapeutics (ACOR) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Acorda Therapeutics (ACOR) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
